Adicet Bio's revenue for the
three
months ended in Dec. 2023 was $0.00 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.
Adicet Bio's Revenue per Share for the
three
months ended in Dec. 2023 was $0.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00.
During the past 6 years, Adicet Bio's highest 3-Year average Revenue per Share Growth Rate was 128.40% per year. The lowest was -9.10% per year. And the median was 59.65% per year.
Adicet Bio Revenue Historical Data
The historical data trend for Adicet Bio's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Adicet Bio's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adicet Bio's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adicet Bio's Revenue distribution charts can be found below:
* The bar in red indicates where Adicet Bio's Revenue falls into.
Adicet Bio Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adicet Bio (LTS:0HX7) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Adicet Bio Revenue Related Terms
Thank you for viewing the detailed overview of Adicet Bio's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. The company operates and manages its business as one reportable and operating segment, which is the business of research and development of allogeneic immunotherapies for cancer and other diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LTS:0HX7 has been successfully added to your 